Daraxonrasib Reaches Metastatic Pancreatic Cancer Patients, Extending Median Survival to 13 Months
Updated
Updated · The Star Online · Aug 23
Daraxonrasib Reaches Metastatic Pancreatic Cancer Patients, Extending Median Survival to 13 Months
3 articles · Updated · The Star Online · Aug 23
Summary
Dozens of U.S. patients with metastatic pancreatic cancer have begun receiving daraxonrasib in recent weeks through an FDA-backed expanded access program, including patients at City of Hope Chicago and UChicago Medicine.
In a recent trial, patients given daraxonrasib after prior treatment lived a median of about 13 months after enrollment, versus about six months for those who received additional chemotherapy.
Doctors called the pill the first targeted therapy available for this disease and said patients also reported better pain, appetite and energy than with chemotherapy.
The drug is not yet FDA-approved; physicians must request it case by case from Revolution Medicines, which is supplying it at no cost to eligible patients.
For patients such as 59-year-old Rachelle Gardner and 84-year-old Mary Louise McAdams, who had exhausted standard options, the program offers time they say conventional treatment could no longer promise.
Could a once-undruggable mutation hold the key to doubling pancreatic cancer survival, and who gets access first?
As an experimental drug doubles survival rates, will its severe side effects overshadow the rare hope it offers?
Daraxonrasib Doubles Survival in Metastatic Pancreatic Cancer: Landmark RASolute 302 Phase 3 Results and the Rise of RAS(ON) Inhibition
Overview
In June 2026, the Phase 3 RASolute 302 trial revealed that daraxonrasib, an oral, once-daily RAS inhibitor, dramatically reduced the risk of death and doubled survival for patients with metastatic pancreatic cancer compared to chemotherapy. This breakthrough was achieved through a unique 'molecular glue' mechanism that blocks active RAS signaling, delivering consistent benefits across different genetic mutations. Daraxonrasib also preserved quality of life and had fewer severe side effects, leading to rapid regulatory progress, including FDA review and an Expanded Access Program reaching thousands of patients. Encouraging early results in first-line treatment are now being tested in a global Phase 3 trial.